Role of androgen deprivation treatment in patients with castration-resistant prostate cancer, receiving docetaxel-based chemotherapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 2, 2011, Pages 140-144

  Lee, Jae Lyun ^a   Kim, Jeong Eun ^a   Ahn, Jin Hee ^a   Lee, Dae Ho ^a   Lee, Junghsin ^a   Kim, Choung Soo ^a   Hong, Jun Hyuk ^a   Hong, Bumsik ^a   Song, Cheryn ^a   Ahn, Hanjong ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Androgen deprivation therapy; Castration resistant prostate cancer; Chemotherapy; Docetaxel; Luteinizing hormone releasing hormone agonist

Indexed keywords

BICALUTAMIDE; CYPROTERONE ACETATE; DOCETAXEL; ESTRAMUSTINE; ESTROGEN; FLUTAMIDE; GONADORELIN AGONIST; KETOCONAZOLE; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; ESTRAMUSTINE; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS; TESTOSTERONE;

EID: 79955948091     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181d2ed7d     Document Type: Article

References (30)

1. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520. (Pubitemid 39315318)
2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512. (Pubitemid 39315317)
3. Bruchovsky N, Brwon EM, Coppin CM. The endocrinology and treatment of prostate tumor progression. In: Coffey DS, Bruchovsky N, Gardner WA, eds. Current Concepts and Approaches to the Study of Prostate Cancer. New York, NY: Liss; 1987:347-387.
4. Isaacs JT, Isaacs WB, Feitz WF, et al. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate. 1986;9:261-281. (Pubitemid 17215900)
5. Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol. 1993;11:2167.
6. Hussain M, Wolf M, Marshall E, et al. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a South-west Oncology Group report. J Clin Oncol. 1994;12:1868-1875.
7. Shamash J, Davies A, Ansell W, et al. A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. Br J Cancer. 2008;98:22-24.
8. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase ii clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Speciflc AntigenWorking Group. J Clin Oncol. 1999;17:3461-3467. (Pubitemid 29517916)
9. Basch EM, Somerfleld MR, Beer TM, et al. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol. 2007;25:5313-5318. (Pubitemid 350232264)
10. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148-1159.
11. Daehlin L, Damber JE, von Schoultz B, et al. The oestrogenic effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate in patients with prostatic carcinoma. A comparative study of oestrogen sensitive liver proteins, gonadotrophins and prolactin. Br J Urol. 1986;58:412-416. (Pubitemid 16044605)
12. Fossa SD, Fossa J, Aakvaag A. Hormone changes in patients with prostatic carcinoma during treatment with estramustine phosphate. J Urol. 1977;118: 1013-1018. (Pubitemid 8261180)
13. Hillner BE, Roberts JD. Role of perspective and other uncertainties in cost-effectiveness assessments in advanced prostate cancer. J Natl Cancer Inst. 2000;92:1704-1706.
14. Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009;27:3452-3458.
15. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448-4456. (Pubitemid 46630983)
16. Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organization for Research and Treatment of Cancer (EORTC) trial 30891. J Clin Oncol. 2006;24:1868-1876. (Pubitemid 46638985)
17. Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab. 2008;93:2042-2049. (Pubitemid 351831513)
18. Tsai HK, D'Amico AV, Sadetsky N, et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99:1516-1524. (Pubitemid 351767235)
19. Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154-164. (Pubitemid 40096612)
20. Strum SB, McDermed JE, Scholz MC, et al. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol. 1997;79:933-941. (Pubitemid 28316762)
21. Vollmer RT, Kantoff PW, Dawson NA, et al. Importance of serum hemoglobin in hormone refractory prostate cancer. Clin Cancer Res. 2002;8:1049-1053. (Pubitemid 35177354)
22. Weight CJ, Klein EA, Jones JS. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population. Cancer. 2008;112:2195-2201. (Pubitemid 351628629)
23. Oefelein MG. Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer. J Urol. 2003;169:251-255. (Pubitemid 35461599)
24. Nejat RJ, Rashid HH, Bagiella E, et al. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol. 2000;164:1891-1894.
25. Pedraza R, Kwart AM. Hormonal therapy for patients with advanced adeno-carcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression? Urology. 2003;61:770-773. (Pubitemid 36384971)
26. Oefelein MG. Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment. Urology. 1999;54:694-699. (Pubitemid 29449432)
27. D'Amico AV, Renshaw A, Loffredo B, et al. Time to return to baseline testosterone level and the risk of death from prostate cancer in men who received radiation and 6 months of androgen suppression therapy. Proc ASCO Prostatic Cancer Symposium. 2007. Abstract 190.
28. Wagmiller JA, Griggs JJ, Dick AW, et al. Individualized strategy for dosing luteinizing hormone-releasing hormone agonists for androgen-independent prostate cancer: identiflcation of outcomes and costs. J Oncol Pract. 2006;2:57-66.
29. Waxman J, Ngan S. Androgen resistance in prostate cancer. Br J Cancer. 2008;98:1.
30. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratu-moral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68:4447-4454.